Logo image of GNFT.PA

GENFIT (GNFT.PA) Stock Price, Quote, News and Overview

EPA:GNFT - Euronext Paris - Matif - FR0004163111 - Common Stock - Currency: EUR

3.92  -0.06 (-1.56%)

GNFT.PA Quote, Performance and Key Statistics

GENFIT

EPA:GNFT (6/4/2025, 7:00:00 PM)

3.92

-0.06 (-1.56%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High5.86
52 Week Low2.62
Market Cap195.46M
Shares49.86M
Float43.25M
Yearly DividendN/A
Dividend YieldN/A
PE130.67
Fwd PEN/A
Earnings (Next)09-22 2025-09-22
IPO12-19 2006-12-19


GNFT.PA short term performance overview.The bars show the price performance of GNFT.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 10

GNFT.PA long term performance overview.The bars show the price performance of GNFT.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 10 -10 20

The current stock price of GNFT.PA is 3.92 EUR. In the past month the price decreased by -1.75%. In the past year, price decreased by -19.18%.

GENFIT / GNFT Daily stock chart

GNFT.PA Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 18.34 292.16B
AMG.DE AMGEN INC 13.95 136.71B
1AMGN.MI AMGEN INC 14.47 135.46B
GIS.DE GILEAD SCIENCES INC 14.11 119.39B
1GILD.MI GILEAD SCIENCES INC 14.1 119.24B
VX1.DE VERTEX PHARMACEUTICALS INC N/A 101.05B
ARGX.BR ARGENX SE 108.09 31.02B
22UA.DE BIONTECH SE-ADR N/A 23.85B
IDP.DE BIOGEN INC 8.39 17.08B
0QF.DE MODERNA INC N/A 9.44B
1MRNA.MI MODERNA INC N/A 9.44B
BIO.DE BIOTEST AG N/A 1.69B

About GNFT.PA

Company Profile

GNFT logo image Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France and currently employs 169 full-time employees. The company went IPO on 2006-12-19. The firm provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The firm leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.

Company Info

GENFIT

Parc Eurasante 885 avenue Eugene Avinee

LOOS HAUTS-DE-FRANCE FR

Employees: 169

GNFT Company Website

GNFT Investor Relations

Phone: 33320164000

GENFIT / GNFT.PA FAQ

What is the stock price of GENFIT today?

The current stock price of GNFT.PA is 3.92 EUR. The price decreased by -1.56% in the last trading session.


What is the ticker symbol for GENFIT stock?

The exchange symbol of GENFIT is GNFT and it is listed on the Euronext Paris - Matif exchange.


On which exchange is GNFT.PA stock listed?

GNFT.PA stock is listed on the Euronext Paris - Matif exchange.


What is the price forecast or stock price prediction for GENFIT stock?

13 analysts have analysed GNFT.PA and the average price target is 9.66 EUR. This implies a price increase of 146.33% is expected in the next year compared to the current price of 3.92. Check the GENFIT stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is GENFIT worth?

GENFIT (GNFT.PA) has a market capitalization of 195.46M EUR. This makes GNFT.PA a Micro Cap stock.


How many employees does GENFIT have?

GENFIT (GNFT.PA) currently has 169 employees.


What are the support and resistance levels for GENFIT (GNFT.PA) stock?

GENFIT (GNFT.PA) has a support level at 3.68 and a resistance level at 3.93. Check the full technical report for a detailed analysis of GNFT.PA support and resistance levels.


Is GENFIT (GNFT.PA) expected to grow?

The Revenue of GENFIT (GNFT.PA) is expected to grow by 3.14% in the next year. Check the estimates tab for more information on the GNFT.PA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy GENFIT (GNFT.PA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does GENFIT (GNFT.PA) stock pay dividends?

GNFT.PA does not pay a dividend.


When does GENFIT (GNFT.PA) report earnings?

GENFIT (GNFT.PA) will report earnings on 2025-09-22.


What is the Price/Earnings (PE) ratio of GENFIT (GNFT.PA)?

The PE ratio for GENFIT (GNFT.PA) is 130.67. This is based on the reported non-GAAP earnings per share of 0.03 and the current share price of 3.92 EUR. Check the full fundamental report for a full analysis of the valuation metrics for GNFT.PA.


GNFT.PA Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to GNFT.PA. When comparing the yearly performance of all stocks, GNFT.PA is a bad performer in the overall market: 72.46% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

GNFT.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to GNFT.PA. GNFT.PA has only an average score on both its financial health and profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

GNFT.PA Financial Highlights

Over the last trailing twelve months GNFT.PA reported a non-GAAP Earnings per Share(EPS) of 0.03. The EPS increased by 105.17% compared to the year before.


Industry RankSector Rank
PM (TTM) 2.12%
ROA 1%
ROE 2.18%
Debt/Equity 0.08
Chartmill High Growth Momentum
EPS Q2Q%-212.5%
Sales Q2Q%-53%
EPS 1Y (TTM)105.17%
Revenue 1Y (TTM)85.82%

GNFT.PA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 91% to GNFT.PA. The Buy consensus is the average rating of analysts ratings from 13 analysts.

For the next year, analysts expect an EPS growth of -118.61% and a revenue growth 3.14% for GNFT.PA


Ownership
Inst Owners0.9%
Ins Owners0.19%
Short Float %N/A
Short RatioN/A
Analysts
Analysts90.77
Price Target9.66 (146.43%)
EPS Next Y-118.61%
Revenue Next Year3.14%